TY - JOUR
T1 - Cefodizime (THR-221) in the field of internal medicine
AU - Kobayashi, Yoshio
AU - Kawabe, Hiroshi
AU - Itaya, Yoshiaki
AU - Fujimori, Ippei
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1988
Y1 - 1988
N2 - Eight patients—5 with acute pneumonia. 1 with chronic bronchitis. 1 with infected bronchiectasis and 1 with acute pyelonephritis due to Escherichia coli-were given 2 g of cefodizime (THR-221), a newly developed cephalosporin antibiotic, b.i.d. intravenously for periods ranging from 8.5∼15.5 days. Of the 5 patients with pneumonia, 4 were successfully treated, but 1 needed further treatment with piperacillin. Sputum culture of 1 of the 4 successfully treated patients revealed Streptococcus pneumoniae. No significant side-effects were observed. Transient elevation of S-GOT, S-GPT, Al-P and γ-GTP was observed in one patient.
AB - Eight patients—5 with acute pneumonia. 1 with chronic bronchitis. 1 with infected bronchiectasis and 1 with acute pyelonephritis due to Escherichia coli-were given 2 g of cefodizime (THR-221), a newly developed cephalosporin antibiotic, b.i.d. intravenously for periods ranging from 8.5∼15.5 days. Of the 5 patients with pneumonia, 4 were successfully treated, but 1 needed further treatment with piperacillin. Sputum culture of 1 of the 4 successfully treated patients revealed Streptococcus pneumoniae. No significant side-effects were observed. Transient elevation of S-GOT, S-GPT, Al-P and γ-GTP was observed in one patient.
UR - http://www.scopus.com/inward/record.url?scp=0023737860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023737860&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.36.Supplement5_400
DO - 10.11250/chemotherapy1953.36.Supplement5_400
M3 - Article
AN - SCOPUS:0023737860
SN - 0009-3165
VL - 36
SP - 400
EP - 404
JO - CHEMOTHERAPY
JF - CHEMOTHERAPY
ER -
